Table 3

Adverse event types and incidence up to 22 weeks

Golimumab+MTX (n=26)Placebo+MTX (n=25)
Subjects with SAE (non study-drug related)01
Subjects with AE/event leading to lower or quit MTX
 Total811
 ALAT elevation26
 Nausea/vomiting42
 Infection23
No of subjects with other treatment-related AE2122
 Liver toxicity25
 Upper airway infections55
 Other infections38
 Headaches11
 Malaise/tiredness around MTX intake55
 Nausea/vomiting1713
 Other88
  • MTX, methotrexate; SAE, Severe adverse event.